CytoMed Therapeutics Ltd
GDTCNasdaq
$1.00
↓ -2.0%Jul 17 close · end-of-day
Price
1Y↓ -50.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
We are a pre-clinical biopharmaceutical company focused on harnessing our licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. As of the date of this Prospectus, the registrant is a public company limited by shares known as CytoMed Therapeutics Limited. On January 19, 2023, the registrant converted from a private company limited by shares incorporated in Singapore, known as CytoMed Therapeutics Pte. Ltd. to a public company limited by shares pursuant to the provisions of the Singapore Companies Act. Our principal executive office in Singapore is located at 1 Commonwealth Lane, #08-22, Singapore.
- CEO
- Chee Kong Choo
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Website
- w2.cytomed.sg
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Feb 6, 2026
Jan 29, 2026
Jan 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-13 | Choo Chee Kong | Buy | 112,000 | $1.15 | $128,777.60 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.